biote Q1 2023 Earnings Report

biote EPS Results

• Actual EPS: $0.94
• Consensus EPS: $0.09
• Beat/Miss: Beat by +$0.85
• One Year Ago EPS: N/A

biote Revenue Results

• Actual Revenue: $44.84 million
• Expected Revenue: $43.38 million
• Beat/Miss: Beat by +$1.46 million
• YoY Revenue Growth: N/A

biote Announcement Details

• Quarter: Q1 2023
• Date: 5/9/2023
• Time: N/A

biote (NASDAQ:BTMD) operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.